CGIX News and Press, Cancer Genetics Inc. From 01/21/21

Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group (MARA) -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain (RIOT) -11% as Bitcoin crumbles despite good news rolls in.Foresight Autonomous (...

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the 2021 BioConnect Virtual Conferenc...

WeissLaw LLP Reminds EIGI, GV, CGIX and ROCH Shareholders About Its Ongoing Investigations PR Newswire NEW YORK , Dec. 18, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigatio...

Oncternal Therapeutics (ONCT) -25% on increasing previously announced bought deal offer to $75.0M.GeoVax Labs (GOVX) -23%.Xenetic Biosciences (XBIO) -21%. on launching $6M registered direct offering priced at-the-market.Savara (SVRA) -19% on providing pipeline and business...

Atossa Therapeutics (ATOS) -42% on announcing pricing of $20M underwritten public offering.Pluristem Therapeutics (PSTI) -42% after DMC recommendation following interim analysis of its Phase III CLI study.Photronics PLAB -18% on Q4 earnings release.Talos Energy TALO -...

Gainers: Curis CRIS +333%, Lexicon Pharmaceuticals LXRX +78%, NeuroMetrix (NURO) +73%,  Cancer Genetics, Inc. (CGIX) +25%, Cantel Medical CMD +17%.Losers: Obalon Therapeutics (OBLN) -19%, Arcturus Therapeutics Holdings ARCT -16%, ...

Curis CRIS +199% on encouraging CA-4948 data in leukemia.NeuroMetrix (NURO) +84%.Stitch Fix SFIX +39% on Q1 results.Lexicon Pharmaceuticals (LXRX) +31%.Cancer Genetics (CGIX) +28%.Smartsheet SMAR +18% on Q3 results.Tarena TEDU +18% on founder's going pr...

WeissLaw LLP Reminds CGIX, ALSK, EIGI, and HDS Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Nov. 30, 2020 NEW YORK , Nov. 30, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would li...

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced today financial and operating results for the quarter ended September 30, 2020....

Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announce...